Semaglutide can yield weight loss, lower heart issues for at least four years in non-diabetic adults with overweight

Two studies are being presented at this year’s European Congress on Obesity (ECO) in Venice, Italy (12-15 May), based on the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author group.

Facebook Comments